AUTHORS
Yazeed Sawalha, MD, Subodh Bhatta, PhD2, Sonia Godbole, MD3, Jarrod Smith, MD4, Shakthi P. Bhaskar, MD5, Andrew P. Jallouk, MD, PhD6, Lorenzo Falchi, MD7, Ayushi Chauhan, MD8, Swetha Thiruvengadam, MD9, Ajay Major, MD, MBA10, Allison Marie Bock, MD11, Matthew A. Lunning, DO, FACP12, Gulrayz Ahmed, MD13, Amy A. Ayers14, Mehdi Hamadani, MD15, Narendranath Epperla, MD, MS, FACP16, Jennifer L. Crombie, MD17, Steven Bair, MD18, Geoffrey Shouse, DO PhD19, Alex Francisco Herrera, MD20, Alexey V. Danilov, MD, PhD21, Christopher R. Flowers Jr, MD, MS22, Gilles Salles I, MD, PhD23, Sairah Ahmed, MD24, Reid W Merryman, MD25
AFFILIATIONS
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 Vanderbilt University, Nashville, United States
5 Vanderbilt University, Nashville, United States
6 Vanderbilt University, Nashville, United States
7 Memorial Sloan Kettering Cancer Center, New York City, United States
8 MD Anderson Cancer Center, Houston, United States
9 City of Hope National Medical Center, Duarte, United States
10 University of Colorado School of Medicine, Denver, United States
11 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
12 University of Nebraska Medical Center, Omaha, United States
13 Medical College of Wisconsin, Milwaukee, United States
14 MD Anderson Cancer Center, Houston, United States
15 Medical College of Wisconsin, Milwaukee, United States
16 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
17 Dana-Farber Cancer Institute, Boston, United States
18 University of Colorado School of Medicine, Denver, United States
19 City of Hope National Medical Center, Duarte, United States
20 City of Hope National Medical Center, Duarte, United States
21 City of Hope National Medical Center, Duarte, United States
22 MD Anderson Cancer Center, Houston, United States
23 Memorial Sloan Kettering Cancer Center, New York City, United States
24 MD Anderson Cancer Center, Houston, United States
25 Dana-Farber Cancer Institute, Boston, United States
ABSTRACT
Background: Although complete responses (CRs) to CD3xCD20 bispecific antibodies (BsAbs) in FL can be durable, the outcomes of patients (pts) who initially achieve a partial response (PR) or stable disease (SD) remain poorly defined. Further, the prognostic significance of the timing of CR achievement remains poorly understood. Here, we evaluated the clinical outcomes of pts with FL who achieve initial PR/SD (iPR/SD) following CD3xCD20 BsAb therapy, specifically analyzing CR conversion rates and the impact of time to CR.
Methods: This is a multicenter retrospective study of adult pts with FL treated with commercial CD3xCD20 BsAbs across 10 US centers within the Collaborative US Bispecific Consortium (CUBIC). Timing of first response assessment (FRA) and response-assessment intervals were at treating physician discretion, with responses evaluated locally per Lugano 2014 criteria. To assess if the time to achieving first CR affects response durability, we compared duration of CR (DoCR; first CR to progression (PD) or death) categorically (initial CR [iCR] vs subsequent [subCR]) and by modeling time to CR as a continuous variable, estimating the hazard ratio (HR) for PD or death per 1-month increase in time to CR. iCR was CR at FRA, and subCR was CR at subsequent RA. Progression-free survival (PFS) and overall survival (OS) were calculated from BsAb initiation.
Results: Among 169 pts, 84% received mosunetuzumab, 14% epcoritamab, and 2% glofitamab. Median number of prior lines of therapy (pLOT) was 3; 23 (14%) had prior CAR T. First response was CR in 82 (57%) pts (iCR cohort), PR in 43 (30%), SD in 5 (4%), PD in 13 (9%), and missing in 26 (15%). PET/CT was used for FRA in 122/130 (94%) pts with CR/PR/SD. 1-year PFS and OS rates for the overall cohort were 70.1% and 94.1%.
Of 48 pts with iPR/SD, median age was 68 (range 33-89); 28 (58%) were male; 4/42 (10%) had performance status (PS) ≥2; 36/44 (82%) stage III/IV; 26/44 (59%) extranodal (EN) disease; 6/41 (14%) bulky disease (≥7 cm); and 16/48 (33%) elevated LDH. Response assessment was by PET/CT in 45 pts (94%), with median time to FRA of 2.1 months (interquartile range [IQR] 1.8-3.4). BsAb was mosunetuzumab (n=42, 88%), epcoritamab (n=5, 10%), or glofitamab (n=1, 2%). Median number of pLOT was 3 (range 0-14); 9 (19%) had prior CAR T.
For the 48 pts with iPR/SD: 21 (44%) converted to CR (subCR cohort) (20/43 [47%] of PR and 1/5 [20%] of SD) after a median of 3.7 months (IQR 3.2-4.8), 6 (13%) remained PR/SD with a median follow-up of 3.7 months (IQR 2.6-5.1), and 14 (29%) progressed without CR after a median of 2.8 months (IQR 1.9-6.0). Others stopped for toxicity (n=2, 4%), transitioned to CAR T (n=1, 2%), or remained on treatment without additional RA (n=3, 6%) (missing, n=1). At 1.2-year median follow-up, the 1-year PFS rate and median PFS for pts with iPR/SD were 62.7% (95% CI: 49.1–80.1) and 1.5 years (95% CI: 0.9-not reached); the 1-year OS rate was 100%. Compared with iCR, pts with iPR/SD had inferior PFS (HR 2.3, 95% CI: 1.2-4.2, p=.01), without significant difference in OS (HR 1.6, 95% CI: 0.3–8, p=.56). 1-year PFS and OS for initial SD vs PR were 40.0% and 100% vs 65.7% and 100% (HRs for PFS: 1.89, 95%CI: 0.55-6.49, p=.31, and for OS: 3.62, 95%CI: 0.33-40.2, p=.29).
In univariable analysis, EN involvement was the only variable that trended toward predicting lower conversion from iPR/SD to CR (HR 4.0, 95% CI: 0.9-21.1, p=.085), with other evaluated variables (age, sex, PS, prior CAR T, stage, number of pLOT, bulky disease, and LDH) showing no significance.
The median time to achieving iCR was 2.1 months (IQR 1.8–2.7) vs 6.1 months (IQR 5.6-7.5) for subCR. At a median post-CR follow-up of 1.2 years for iCR and 1.0 year for subCR, the 1-year DoCR rates were similar: subCR: 86.3%, 95% CI: 70.1–100 vs iCR: 81.4%, 95% CI: 71.8–92.2; HR 1.16, p=.77. When analyzed as a continuous variable, time to first CR was not significantly associated with DoCR (HR 0.89 per month increase, 95% CI: 0.71–1.12, p=.33).
Conclusions: A significant proportion (44%) of pts with FL who achieve initial PR/SD with CD3xCD20 BsAb eventually convert to CR, though EN involvement may predict lower conversion rates. Although pts with initial PR/SD have inferior PFS, those who convert to CR achieve durable outcomes comparable to those with an initial CR, and timing to CR does not impact outcomes. These findings highlight the therapeutic value of continuing treatment in pts with initial PR/SD.
DISCLOSURES
Yazeed Sawalha, MD: BeOne - Research Funding; AbbVie - Research Funding; Genmab - Research Funding; BeOne - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); ADC - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)